Browsing by Author "Salim Berkinbayev"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • No Thumbnail Available
    PublicationMetadata only
    Repositioning of the global epicentre of non-optimal cholesterol
    (2020-06-04) Cristina Taddei; Bin Zhou; Honor Bixby; Rodrigo M. Carrillo-Larco; Goodarz Danaei; Rod T. Jackson; Farshad Farzadfar; Marisa K. Sophiea; Mariachiara Di Cesare; Maria Laura Caminia Iurilli; Andrea Rodriguez Martinez; Golaleh Asghari; Klodian Dhana; Pablo Gulayin; Sujay Kakarmath; Marilina Santero; Trudy Voortman; Leanne M. Riley; Melanie J. Cowan; Stefan Savin; James E. Bennett; Gretchen A. Stevens; Christopher J. Paciorek; Wichai Aekplakorn; Renata Cifkova; Simona Giampaoli; Andre Pascal Kengne; Young Ho Khang; Kari Kuulasmaa; Avula Laxmaiah; Paula Margozzini; Prashant Mathur; Børge G. Nordestgaard; Dong Zhao; Mette Aadahl; Leandra Abarca-Gómez; Hanan Abdul Rahim; Niveen M. Abu-Rmeileh; Benjamin Acosta-Cazares; Robert J. Adams; Imelda A. Agdeppa; Javad Aghazadeh-Attari; Carlos A. Aguilar-Salinas; Charles Agyemang; Tarunveer S. Ahluwalia; Noor Ani Ahmad; Ali Ahmadi; Naser Ahmadi; Soheir H. Ahmed; Wolfgang Ahrens; Kamel Ajlouni; Monira Alarouj; Fadia AlBuhairan; Shahla AlDhukair; Mohamed M. Ali; Abdullah Alkandari; Ala’a Alkerwi; Eman Aly; Deepak N. Amarapurkar; Philippe Amouyel; Lars Bo Andersen; Sigmund A. Anderssen; Ranjit Mohan Anjana; Alireza Ansari-Moghaddam; Hajer Aounallah-Skhiri; Joana Araújo; Inger Ariansen; Tahir Aris; Raphael E. Arku; Nimmathota Arlappa; Krishna K. Aryal; Thor Aspelund; Maria Cecília F. Assunção; Juha Auvinen; Mária Avdicová; Ana Azevedo; Fereidoun Azizi; Mehrdad Azmin; Nagalla Balakrishna; Mohamed Bamoshmoosh; Maciej Banach; Piotr Bandosz; José R. Banegas; Carlo M. Barbagallo; Alberto Barceló; Amina Barkat; Iqbal Bata; Anwar M. Batieha; Assembekov Batyrbek; Louise A. Baur; Robert Beaglehole; Antonisamy Belavendra; Habiba Ben Romdhane; Mikhail Benet; Marianne Benn; Salim Berkinbayev; Antonio Bernabe-Ortiz; Gailute Bernotiene; Heloisa Bettiol; Santosh K. Bhargava; Dasman Diabetes Institute; University of Science and Technology, Yemen; Western Norway University of Applied Sciences; Lietuvos sveikatos mokslų universitetas; Kazakh National Medical University; Université de Lille; Caja Costarricense de Seguro Social; Beijing Anzhen Hospital, Capital Medical University; Qatar University; Birzeit University; Luxembourg Institute of Health; Al Farabi Kazakh National University; Food and Nutrition Research Institute Manila; Universidad Peruana Cayetano Heredia; Haskoli Islands; Jordan University of Science and Technology; Institute for Clinical Effectiveness and Health Policy, Ciudad Autonoma de Buenos Aires; University of Tunis El Manar; National Center for Diabetes, Endocrinology and Genetics Jordan; Harvard T.H. Chan School of Public Health; Erasmus MC; Zahedan University of Medical Sciences; Pontificia Universidad Católica de Chile; South African Medical Research Council; Tehran University of Medical Sciences; Organisation Mondiale de la Santé; Universidad Autónoma de Madrid; The University of Sydney; Indian Council of Medical Research; University of California, Berkeley; Shahid Beheshti University of Medical Sciences, Research Institute for Endocrine Science; Shahrekord University of Medical Sciences; Urmia University of Medical Sciences; Flinders University; Mohammed V University in Rabat; Shahid Beheshti University of Medical Sciences; Rush University Medical Center; Università degli Studi di Palermo; National Institute of Nutrition India; Oulu University Hospital; Charles University; Steno Diabetes Center Copenhagen; Dalhousie University; Copenhagen University Hospital; Imperial College London; Universidade Federal de Pelotas; University of Massachusetts Amherst; Middlesex University; Pan American Health Organization; Seoul National University; Oulun Yliopisto; Kementerian Kesihatan Malaysia; Mahidol University; Gdanski Uniwersytet Medyczny; Norwegian Institute of Public Health; Bombay Hospital and Medical Research Centre; Universitetet i Oslo; Istituto Superiore Di Sanita; Instituto Nacional de la Nutrición Salvador Zubiran; Instituto Mexicano del Seguro Social; University of Bremen; Universidade de Sao Paulo - USP; Universidade do Porto; Frederiksberg Hospital; Medical University of Lodz; University of Auckland; Norges idrettshøgskole; Harvard Medical School; Universiteit van Amsterdam; Christian Medical College, Vellore; Madras Diabetes Research Foundation; Abt Associates; Independent Researcher; Aldara Hospital and Medical Center; Cafam University Foundation; Finnish Institute for Health and Welfare; National Institute of Public Health; King Abdullah International Medical Research Center; Thomayer Hospital; Regional Authority of Public Health; Sunder Lal Jain Hospital
    © 2020, The Author(s), under exclusive licence to Springer Nature Limited. High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health4,5. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol—which is a marker of cardiovascular risk—changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million–4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.